Review





Similar Products

pcr restriction fragment length polymorphism rflp hin1ii nlaiii cleavage sites  (New England Biolabs)
96
New England Biolabs pcr restriction fragment length polymorphism rflp hin1ii nlaiii cleavage sites
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Restriction Fragment Length Polymorphism Rflp Hin1ii Nlaiii Cleavage Sites, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr restriction fragment length polymorphism rflp hin1ii nlaiii cleavage sites/product/New England Biolabs
Average 96 stars, based on 1 article reviews
pcr restriction fragment length polymorphism rflp hin1ii nlaiii cleavage sites - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pcr product purification kit  (TaKaRa)
96
TaKaRa pcr product purification kit
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Product Purification Kit, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr product purification kit/product/TaKaRa
Average 96 stars, based on 1 article reviews
pcr product purification kit - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pcr fragments  (New England Biolabs)
99
New England Biolabs pcr fragments
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Fragments, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr fragments/product/New England Biolabs
Average 99 stars, based on 1 article reviews
pcr fragments - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
pcr fragment  (New England Biolabs)
96
New England Biolabs pcr fragment
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Fragment, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr fragment/product/New England Biolabs
Average 96 stars, based on 1 article reviews
pcr fragment - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pcr amplified dna fragments  (New England Biolabs)
97
New England Biolabs pcr amplified dna fragments
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Amplified Dna Fragments, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr amplified dna fragments/product/New England Biolabs
Average 97 stars, based on 1 article reviews
pcr amplified dna fragments - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
pcr amplified dna fragments  (Thermo Fisher)
99
Thermo Fisher pcr amplified dna fragments
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Amplified Dna Fragments, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr amplified dna fragments/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
pcr amplified dna fragments - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
pcr fragment purification kit  (TaKaRa)
96
TaKaRa pcr fragment purification kit
Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with <t>HIN1II.</t> (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.
Pcr Fragment Purification Kit, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr fragment purification kit/product/TaKaRa
Average 96 stars, based on 1 article reviews
pcr fragment purification kit - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with HIN1II. (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.

Journal: Frontiers in Oncology

Article Title: Studies on the functionality of the TC-NER ERCC6-M1097V protein variant frequently found in Louisiana patients with PCa upon UV damage

doi: 10.3389/fonc.2025.1679379

Figure Lengend Snippet: Generation and validation of the M1097V knock-in in prostate cancer cells using the CRISPR/Cas9 editing system. (A) A schematic diagram of the recurring ERCC6 M1097V mutation, created with BioRender. (B) A schematic diagram of the CRISPR/Cas9 editing system, made with BioRender. (C) PCR amplification of the M1097V region and cleavage with HIN1II. (D) Confirmation of the cleavage site using the ERCC6 plasmid from Origene. (E) Clone confirmation after generating the M1097V variants with CRISPR/Cas9 via PCR-RFLP. Graphical sketch prepared with BioRender.

Article Snippet: PCR-restriction fragment length polymorphism (RFLP) Hin1II (NlaIII) cleavage sites were identified in our expected amplicons using the New England Biolabs NEBcutter tool.

Techniques: Biomarker Discovery, Knock-In, CRISPR, Mutagenesis, Amplification, Plasmid Preparation